{"id":29879,"date":"2016-03-22T09:29:12","date_gmt":"2016-03-22T09:29:12","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=29879"},"modified":"2016-06-07T17:33:43","modified_gmt":"2016-06-07T17:33:43","slug":"23rd-conference-on-retroviruses-and-opportunistic-infections-croi-2016-22-25-february-2016-boston-2","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/29879","title":{"rendered":"23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-29668\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2016\/02\/CROI-logo2-no-key.png\" alt=\"CROI logo2 no key\" width=\"200\" height=\"202\" \/><\/p>\n<p><strong>Every year, CROI brings more than 5000 researchers, doctors, community activists and other health workers to meet for one of the most scientifically important HIV conferences.<\/strong><\/p>\n<p>This year the meeting was in Boston and with over 1000 studies presented, there is far more to report than the key studies that make headline news.<\/p>\n<p>At CROI 2016, major studies presented research on basic and clinical science relating to prevention, new treatment and global access.<\/p>\n<p>The programme and abstracts are posted to the conference website, with many posters also available as PDF files.<\/p>\n<p>Webcasts from all oral presentations are also online.<\/p>\n<p><a href=\"http:\/\/www.croiconference.org\/electronic-materials\">http:\/\/www.croiconference.org\/electronic-materials<\/a><\/p>\n<p><a href=\"http:\/\/www.croiconference.org\/abstracts\/search-abstracts\/\">http:\/\/www.croiconference.org\/abstracts\/search-abstracts\/<\/a><\/p>\n<p><a href=\"http:\/\/www.croiconference.org\">http:\/\/www.croiconference.org<\/a><\/p>\n<p>Reports in this issue of HTB are:<\/p>\n<ul>\n<li><a href=\"https:\/\/i-base.info\/htb\/29778\">Dual long-acting injections of cabotegravir plus rilpivirine: 32-week results from LATTE-2 study<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29774\">New NRTI MK-8591: weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29784\">Similar viral load reductions at week 4 when dolutegravir is used with 2- or 3-drug initial ART<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29870\">48-week results for NNRTI doravirine compared to efavirenz<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29700\">Dramatic increase in use of oral TDF\/FTC for PrEP in the US &#8211; plus a few cautions<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29735\">Future oral and long-acting PrEP: pills, films, gels, injections and depots<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29714\">First data on TAF as PrEP to prevent HIV infection<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29717\">Longacting cabotegravir as PrEP protects macaques against IV exposure but will need two-monthly injections in human studies<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29729\">Role for maraviroc as HIV PrEP likely need dual combinations<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29667\">Dapivirine vaginal ring shows only limited PrEP protection against HIV for African women<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29856\">Early data from dolutegravir use during pregnancy<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29757\">Dolutegravir: 48 week results in children aged 6 to 12 years<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29670\">New antiretrovirals could mean savings up to US $3 billion by 2025<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29849\">Countries with lower HIV prevalence have lower ART coverage<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29847\">Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/29794\">Cure research news from CROI 2016<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Reports from CROI 2016 covering dozens of key studies: PrEP, new drugs, access and cure&#8230;<\/p>\n","protected":false},"author":2,"featured_media":27952,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[217,12],"class_list":["post-29879","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-conference-reports","tag-croi-2016","tag-conference-index"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=29879"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29879\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media\/27952"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=29879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=29879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=29879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}